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Introduction
Long-term safety has become a central issue in 
the selection of prostate cancer treatments, for 
several reasons. Prostate cancer mostly affects 
older men, with a median age at diagnosis of 68 
years [Mottet et al. 2015]. The percentage of the 
population aged ⩾65 years is rapidly growing, 
and it is estimated that by year 2040 it will repre-
sent 14% of the overall population worldwide, 
compared with 7% recorded in 2008 [Kinsella 
and Wan, 2009]. The proportion of men with 
5-year survival after prostate cancer diagnosis has 
also increased considerably in the last two dec-
ades, with data from Italian registries document-
ing an increase from 79.1% between 1995 and 
1999 to 89.7% between 2005 and 2009 [Allemani 
et al. 2015], and further improvement of survival 
is expected after the recent introduction of a 
number of new treatment options, especially in 
the metastatic disease setting [Sternberg et  al. 
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Background: We aimed to evaluate the long-term safety profile of abiraterone in patients 
with metastatic castration-resistant prostate cancer (mCRPC) with controlled cardiovascular 
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as the appearance of a symptomatic CE that required medical intervention.
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dyslipidaemia (18%) and type 2 diabetes mellitus (12%). No CEs were recorded and no changes 
in LVEF were observed. The most frequently reported adverse events were Grade 1–2 fluid 
retention (18%), hypertension (16%) and asthenia (16%). No patients permanently discontinued 
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cardiovascular conditions from baseline over an extended observation period.
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2014b]. The ageing of the population and the 
improved life expectancy are generating an 
increasingly larger subgroup of men with 
advanced age who require prostate cancer ther-
apy for longer periods of time. Although it is gen-
erally agreed that older age (whatever cut-off 
point one decides to use to define ‘elderly’) does 
not reduce the chance of benefit from systemic 
therapy [Mottet et  al. 2015; Suzman and 
Eisenberger, 2014], selecting an appropriate and 
well tolerated treatment in this patient popula-
tion can be challenging. As age increases, so does 
the likelihood of frailty, comedication and comor-
bidities, making this age group particularly vul-
nerable to the potential toxicity of anticancer 
drugs [Falci et al. 2009; Sajid et al. 2011]. Patients 
with metastatic prostate cancer show a high prev-
alence of cardiovascular comorbidities [Gandaglia 
et al. 2015], and cardiovascular disease is known 
to be the most common cause of nonprostate 
cancer-related death [Groome et al. 2011]. It is 
necessary, therefore, for a careful assessment of 
the impact that drugs used in this context might 
have on the cardiovascular risk of treatment 
candidates.
While the correlation between androgen depriva-
tion therapy and cardiovascular toxicity remains a 
controversial topic [Alibhai, 2011; Bourke et  al. 
2013; Iacovelli et  al. 2015], much attention has 
been focused in recent years on the new hormo-
nal agents, abiraterone acetate and enzalutamide, 
that have changed treatment paradigms in 
patients with metastatic castration-resistant pros-
tate cancer (mCRPC). Abiraterone inhibits tes-
tosterone production by inhibiting CYP-17, an 
enzyme expressed in gonadal, adrenal and pros-
tatic tumour tissues. Its mechanism of action 
leads to a rebound increase in adrenocorticotropic 
hormone (ACTH) levels, resulting in mineralo-
corticoid excess (a process which is mitigated by 
coadministration of corticosteroids) [Attard et al. 
2012]. Mainly for this reason, there are concerns 
that abiraterone therapy might increase the risk of 
cardiovascular adverse events, especially in pre-
disposed subjects. In fact, data on the cardiovas-
cular safety of abiraterone obtained during clinical 
development have been largely reassuring [Hoy, 
2013]. In pivotal phase III trials, abiraterone plus 
prednisone significantly increased survival in 
mCRPC patients, both chemotherapy-naïve and 
post-docetaxel, while demonstrating a favourable 
tolerability profile, although fluid retention, 
hypokalaemia, hypertension and cardiac events 
(CE) were reported in a higher percentage 
of abiraterone-treated patients compared with 
placebo [Fizazi et al. 2012; Ryan et al. 2015]. A 
recent meta-analysis found an increased risk of 
cardiovascular toxicity associated with the use of 
new hormonal agents versus placebo [relative risk 
(RR) 1.32, 95% CI 1.08–1.60; p = 0.006], 
although the absolute difference in the incidence 
of CEs was small [Iacovelli et al. 2015]. However, 
patients taking part in clinical trials are generally 
selected to exclude cardiovascular comorbidities 
and thus are not necessarily representative of the 
population encountered in real-world practice. 
To the best of the authors’ knowledge, no pro-
spective studies have been conducted on the 
safety of abiraterone in patients with cardiovascu-
lar comorbidities.
In a previously published study, we retrospec-
tively assessed the safety of abiraterone in a real-
world cohort of consecutive patients with mCRPC 
and concomitant cardiovascular diseases or risk 
factors treated at our institution over a 21-month 
follow-up period [Procopio et  al. 2015]. In this 
paper, we report conclusive safety data in this 
patient population after an extended observation 
period up to 4 years.
Patients and methods
The charts of patients with histologically-con-
firmed mCRPC who had been treated with abira-
terone at our institution between April 2011 and 
July 2015 and had ⩾1 concomitant controlled 
cardiovascular diseases or cardiovascular risk fac-
tors were reviewed. Cardiovascular comorbidities 
and risk factors for consideration in our study 
were defined according to the indications of the 
European Society of Cardiology (ESC) and 
included hypertension [defined as a repeated ele-
vation in blood pressure (BP) exceeding 140 over 
90 mmHg], cardiac ischaemia, rhythm disorders, 
valvular disorders, stroke, thrombosis, peripheral 
vascular disease, diabetes, hypercholesterolae-
mia, smoking and obesity. ESC risk charts were 
used to assess the cardiovascular risk of the 
observed population.
Full details of the study methods have been pub-
lished previously [Procopio et al. 2015]. Briefly, 
patients were ⩾18 years old, had received ⩾1 
docetaxel-based regimen, their Eastern 
Cooperative Oncology group (ECOG) perfor-
mance status (PS) was ⩽2 and their life expec-
tancy was ⩾3 months. Patients with brain 
metastases or concomitant illnesses other than 
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controlled cardiovascular diseases, including 
serious respiratory diseases, unstable angina, 
uncontrolled hypertension (defined as ⩾160 
mmHg systolic BP or ⩾90 mmHg diastolic BP 
unresponsive to medical treatment), unstable 
diabetes mellitus, serious infections or autoim-
mune disorders, were excluded.
At baseline, patients were screened for the pres-
ence of cardiac risk factors as part of the clinical 
assessment, and a cardiologist performed an 
electrocardiogram (ECG) and an echocardio-
graphic examination, which included measure-
ment of the left ventricular ejection fraction 
(LVEF). ECG and echocardiographic evalua-
tion were repeated at the end of the treatment 
period. BP was measured at baseline and patients 
were instructed to take daily measurements at 
home and keep a record of the values obtained. 
CEs were defined, according to Common 
Terminology Criteria for Adverse Events version 
4.0, as the appearance of a symptomatic CE 
(hypertension grade ⩾2, heart failure, myocar-
dial infarction, angina, rhythm disorders) that 
required medical intervention.
Patients received oral treatment with abiraterone 
1000 mg once daily plus prednisone 5 mg twice 
daily until disease progression, symptomatic dete-
rioration or onset of unacceptable toxicity. In case 
of grade 3–4 toxicities considered to be treatment 
related, abiraterone was reduced to a daily dose of 
500 mg or temporarily discontinued. If no recov-
ery to grade 0–1 toxicity was achieved within 2 
weeks, treatment was permanently discontinued. 
Efficacy assessments, based on evaluation of bio-
chemical and objective response, were made at 
3-monthly intervals. Biochemical response was 
defined as partial response [(PR) ⩾50% prostate-
specific antigen (PSA) reduction from baseline], 
complete response [(CR) PSA normalization], 
progressive disease [(PD) ⩾50% PSA increase 
from baseline] or stable disease [(SD), any other 
PSA variation]. Radiological objective response 
was assessed by computed tomography or bone 
scan according to Response Evaluation Criteria 
in Solid Tumours (RECIST) version 1.1 criteria 
[Eisenhauer et  al. 2009] and Prostate Cancer 
Clinical Trials Working Group (PCWG2) criteria 
[Scher et al. 2008].
The study protocol was approved by the 
Institutional Review Board and all patients 
included in the study provided written informed 
consent.
Data regarding safety and efficacy were indepen-
dently extracted from standardized forms. 
Descriptive statistics were used to analyse all 
clinical and instrumental variables (mean, stand-
ard deviation, minimum–maximum values for 
continuous variables, and absolute and relative 
frequencies for categorical variables).
Results
A total of 51 patients with mCRPC and cardio-
vascular comorbidities or risk factors who were 
treated with abiraterone between April 2011 and 
July 2015 were included in our analysis. The 
patients’ baseline characteristics are summarized 
in Table 1. Median age was 71 years, mean PSA 
was 154 ng/ml and most patients had metastatic 
bone disease (74%). Prior to abiraterone, 
patients had received ⩾2 lines of hormonal ther-
apy and ⩾1 docetaxel-based chemotherapy regi-
men. Cardiovascular comorbidities or risk 
factors are summarized in Table 2. The most 
frequent pre-existing cardiovascular diseases 
were hypertension (41%), cardiac ischaemia 
(12%) and stroke (9%). Among patients with 
cardiovascular risk factors, 39% were over-
weight, 31% were heavy smokers (>20 ciga-
rettes/day), 30% had hyperglycaemia, 18% had 
dyslipidaemia and 12% had type 2 diabetes mel-
litus. Cardiovascular comorbidities and risk fac-
tors had been present for ⩾1 year. Overall, the 
risk to develop fatal cardiovascular diseases was 
⩽4%, as calculated from ESC score risk charts 
for 82.3% of patients. During the study, cardio-
vascular comorbidities and risk factors were con-
trolled by using appropriate medical treatment, 
including antihypertensive therapies (e.g. ACE 
inhibitors, angiotensin II receptor antagonists, 
β-blockers, calcium antagonists or diuretics), 
statins, metformin and insulin. Most patients 
(71%) who were treated for cardiovascular con-
ditions received a monotherapy.
During the observation period, no CEs were 
recorded and no changes in LVEF were observed 
in the final echocardiographic evaluation. All 
recorded adverse events are reported in Table 3. 
The most common adverse events were grade 
1–2 fluid retention (18%), hypertension (16%) 
and asthenia (16%). The only grade 3–4 adverse 
events were asthenia, skin disorders (2 patients 
each) and nausea (1 patient). The reason for abi-
raterone discontinuation was disease progres-
sion. No patients permanently discontinued 
abiraterone due to adverse events. A dose 
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reduction to 500 mg/day was needed in 5 (9.8%) 
patients.
At the end of the follow-up period (July 2015), 
12 (23%) patients were alive and 3 (6%) were 
still receiving abiraterone. Median follow up for 
alive patients was 33 months (range 12–48 
months) and median duration of abiraterone 
exposure was 16 months (range 9–21 months). 
For all deceased patients, the cause of death was 
prostate cancer.
As for the efficacy analysis, the median duration 
of overall survival was 19 months. PSA assess-
ment showed CR in 5 (9%) patients, PR in 19 
(37.4%), SD in 9 (17%) and PD in 18 (35%). Of 
the 25 patients (49%) evaluable for radiological 
response, 5 (20%) had PR, 10 (40%) had SD and 
10 (40%) had PD.
Discussion
A favourable tolerability profile is crucial for an 
anticancer drug, such as abiraterone, which is 
used very often in elderly patients, including 
those who are considered unsuitable for chemo-
therapy because of their increased vulnerability 
to the adverse event spectrum of cytotoxic regi-
mens [Sajid et al. 2011; Falci et al. 2009]. In our 
study, long-term exposure (median 16 months) 
Table 1. Demographic and clinical characteristics of 
the study cohort (n = 51) at baseline.
Characteristic Median (range)
Age (years) 71 (51–85)
Gleason score 4 + 4 (1 + 2–5 + 5)
PSA (ng/ml) 154 (6.4–2634)
ECOG performance status 1 (0–2)
Metastatic sites, n (%)
 Bone only 19 (37)
  Other (lung + liver + 
nodes)
13 (26)
 Bone + other 19 (37)
Previous lines of therapy, n (%)
 Hormonal therapy
  1 30 (59)
  >1 21 (41)
 Chemotherapy
  1 26 (51)
  >1 25 (49)
ECOG, Eastern Cooperative Oncology Group; PSA, 
prostate-specific antigen.
Table 2. Pre-existing cardiovascular comorbidities 
and risk factors in the study population.
n (%)
Hypertension 21 (41)
 Controlled 20 (39)
 Uncontrolled 1 (2)
Cardiac ischaemia 6 (12)
Rhythm disorders 3 (6)
Vascular disorders 3 (6)
Stroke 5 (9)
Thrombosis 4 (7)
Peripheral vascular disease 2 (4)
Hyperglycaemia 15 (30)
Type 2 diabetes mellitus 6 (12)
Hypercholesterolaemia 9 (18)
Smoker status
 Never smoker 16 (31)
 Smoker 25 (49)
  >20 cigarettes/day 16 (31)
  ⩽20 cigarettes/day 9 (18)
 Former smoker 10 (20)
  >20 cigarettes/day 5 (10)
  ⩽20 cigarettes/day 5 (10)
BMI
 Normal BMI 31 (61)
 Overweight 20 (39)
   Obesity class I (BMI ⩾ 30 but <35 
kg/m2)
10 (20)
   Obesity class II (BMI ⩾ 35 but <40 
kg/m2)
6 (12)
   Obesity class III (BMI ⩾ 40 kg/m2) 4 (8)
BMI, Body mass index.
to abiraterone in mCRPC docetaxel-pretreated 
patients with low-risk, controlled cardiovascular 
comorbidities or risk factors resulted to be safe 
and well tolerated. Over a median observation 
period of 36 months, no cardiovascular deaths 
or emergent symptomatic CEs were reported 
and no clinically significant changes in echocar-
diographic parameters (including LVEF) were 
observed. In particular, there was no apparent 
trend towards increased toxicity with the length-
ening of the period of drug exposure from 12–
24 months [Procopio et al. 2015]. As expected 
from the known effect of abiraterone on miner-
alocorticoid excess, fluid retention and hyper-
tension were the most frequently reported 
adverse events (16–18%). Most adverse events 
were mild (grade 1–2) and only in a few patients 
were asthenia, skin rash and nausea associated 
with grade 3–4 severity (2–3%). No patients 
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required permanent drug withdrawal due to 
adverse events.
Specific information on the cardiovascular safety 
of abiraterone is scarce. In an exploratory phase 
Ib study aimed at assessing the effect of abirater-
one plus prednisone on QT/QTc intervals in 
mCRPC patients by using pharmacokinetic and 
time-matched ECGs, no clinically significant 
changes in the QT/QTc interval were observed, 
suggesting that abiraterone does not substantially 
affect ventricular repolarization and has, there-
fore, a low potential for inducing arrhythmias 
(especially torsade de pointes) [Tolcher et  al. 
2012]. Safety data extracted from both con-
trolled clinical trials and retrospective studies 
show a good tolerability profile of abiraterone 
regarding cardiac events, also in elderly patients 
receiving this drug after multiple lines of previ-
ous therapies. In the COU-AA-301 study in 
mCRPC patients post-docetaxel, mineralocorti-
coid-related events were slightly more frequent 
in the abiraterone arm compared with placebo 
(fluid retention 33% versus 24%, hypertension 
11% versus 8%, hypokalaemia 18% versus 9%, 
respectively) [Fizazi et  al. 2012]. The overall 
incidence of cardiac events was not significantly 
increased by abiraterone (16% versus 12%), 
although cardiac failure was reported more fre-
quently in abiraterone recipients (2.1% versus 
0.7% in placebo), and tachycardia and atrial 
fibrillation were the most commonly reported 
cardiac adverse events [Fizazi et  al. 2012; 
Mostaghel and Lin, 2014]. A post-hoc subgroup 
analysis of the COU-AA-301 trial focused on the 
patients aged ⩾75 years found that the incidence 
of hypertension and hypokalaemia was unaf-
fected by age, while a slightly higher percentage 
of elderly patients in the abiraterone arm, com-
pared with placebo, experienced atrial fibrillation 
(5% versus 1%) and tachycardia (5% versus 2%), 
a difference that was not observed in the younger 
(<75 years) patients group [Mulders et al. 2014]. 
When the results of the COU-AA-301 trial about 
the clinical benefits of abiraterone were first 
reported, a number of protocols were established 
worldwide with the aim to grant preapproval 
access to abiraterone in post-docetaxel mCRPC 
patients for whom no alternative treatment was 
available. Retrospective analyses of the efficacy 
and safety of abiraterone in the unselected patient 
populations who were treated in the context of 
these protocols document a favourable cardio-
vascular tolerability profile. In a multicentre 
early-access protocol trial which involved >2300 
patients from 23 countries, grade 3 hypertension 
was reported in 4% of patients, grade 3 and 
grade 4 cardiac events were reported in 2% 
and <1%, respectively, and grade 3 and grade 4 
fluid retention in 1% and <1%, after a median 
follow up of 5.7 months (there were no available 
data about grade 1–2 adverse events) [Sternberg 
et al. 2014a]. Among the 265 patients who took 
part in the Italian Named Patient Programme, of 
whom many presented cardiovascular comorbid-
ities or risk factors, the incidence of all-grades 
cardiovascular toxicities, over a median 12-month 
follow-up period, was 7.9% for oedema, 2.6% 
for hypertension and 3.8% for cardiac events. No 
grade 3–4 cardiac events were reported, and 
grade 4 hypertension was recorded in only 
1 patient (0.4%) [Caffo et al. 2015]. Interestingly, 
when data from patients aged ⩾80 years who 
took part in this compassionate use programme 
were analysed separately, no substantial differ-
ences from the younger group were found regard-
ing the incidence of adverse events [Maines et al. 
2015]. In the Belgian compassionate use pro-
gram, the records from 368 patients showed a 
higher rate of grade ⩾3 hyperkalaemia and 
hypertension (7.3% and 3.5%, respectively) 
compared with the COU-AA-301 study data 
(4.4% and 1.3%, respectively) [van Praet et  al. 
2016]. Grade ⩾3 cardiac events, however, 
were reported less frequently in the Belgian 
retrospective study versus the phase III trial 
(0.8% versus 5.2%), probably partly due to the 
protocol-required intensive monitoring that was 
adopted in the clinical trial.
Despite the largely favourable data that have 
emerged so far on the cardiovascular tolerability 
of abiraterone, caution is needed. A recently 
Table 3. Adverse events associated with abiraterone 
treatment.
Adverse event Patients, n (%)
Grade 1–2 Grade 3–4
Fluid retention 9 (18) 0
Hypertension 8 (16) 0
Asthenia 8 (16) 2 (3)
Abdominal pain 2 (4) 0
Pruritus and 
cutaneous rash
1 (2) 2 (3)
Nausea 1 (2) 1 (2)
Anaemia 1 (2) 0
Diarrhoea 1 (2) 0
Therapeutic Advances in Medical Oncology 8(5)
328 http://tam.sagepub.com
published meta-analysis on the incidence and 
relative risk of cardiovascular toxicity associated 
with the use of new hormonal agents, enzaluta-
mide, abiraterone and orteronel (the latter’s 
development now having been discontinued) in 
mCRPC patients, found an overall significant 
increase in the risk of cardiac toxicity and hyper-
tension versus placebo, with notable differences 
between drugs [Iacovelli et  al. 2015]. CYP-17 
inhibitors were associated with an increased risk 
of cardiac events, while enzalutamide was linked 
with an increased risk of hypertension.
The findings of our study in a specific group of 
real-world-practice mCRPC patients with car-
diovascular comorbidities or risk factors, who 
are generally excluded from participation in con-
trolled clinical trials, provide some useful infor-
mation on the safety of abiraterone. Notably, 
there were no treatment-emergent cardiac events 
being recorded during exposure to abiraterone, 
nor did we observe, over an extended follow-up 
period, the development of signs or symptoms of 
cardiotoxicity in predisposed patients. This is an 
important aspect, especially when considering 
that abiraterone is now generally introduced in 
much earlier phases of prostate cancer, before 
chemotherapy, and patients may thus be facing a 
long period of treatment with this drug, often 
lasting a few years. Of course, our study has 
many limitations, mostly its retrospective nature, 
the limited number of patients who were fol-
lowed, and the lack of a control group. In par-
ticular, it would have been interesting to compare 
data from our cohort with those of a matched 
group of patients who did not have concomitant 
cardiovascular comorbidities or risk factors. 
Such detailed analysis, however, was precluded 
by the limited number of age-matched mCRPC 
patients without pre-existing cardiovascular risk 
factors who were treated in our centre in the 
timeframe considered. We are also aware that 
the frequency of examinations may affect results 
related to cardiovascular endpoints, as high-
lighted by van Praet and colleagues [van Praet 
et  al. 2016]. In our study, as in daily clinical 
practice, cardiac examinations were not rou-
tinely performed in the absence of symptoms, 
and this may have caused bias toward a lower 
rate of cardiac events compared with phase III 
clinical trials. However, it is still unclear how to 
best monitor cardiovascular function in patients 
with risk factors undergoing abiraterone treat-
ment (i.e. imaging techniques, measurement of 
cardiac biomarkers such as troponins or B-type 
natriuretic peptide) or, indeed, whether an 
intensive monitoring is justified in clinical prac-
tice. Clearly, more research on the subject would 
be useful. At present, based on indications from 
guidelines and expert opinion, pretreatment 
assessment of cardiovascular function with ECG 
and echocardiography deserves consideration in 
elderly patients with reduced cardiac function; 
during treatment, monitoring for hypertension, 
hypokalaemia and fluid retention is recom-
mended at least on a monthly basis, and symp-
tom-directed monitoring for cardiac disease 
should be adequate in patients with pre-existing 
cardiovascular disease [NCCN Guidelines, 
2016; Mostaghel and Lin, 2014].
Conclusion
Long-term abiraterone treatment was well toler-
ated in mCRPC patients with nonserious, con-
trolled cardiovascular comorbidities or risk factors 
who had previously received docetaxel-based 
chemotherapy. No treatment-emergent cardiac 
events were recorded and there was no apparent 
worsening of cardiovascular conditions from 
baseline over an extended observation period, 
suggesting that, provided that cardiac illnesses are 
adequately stabilized with appropriate therapies 
before starting abiraterone and adequately moni-
tored thereafter, patients with mCRPC who are 
considered suitable candidates for hormonal 
agents should not be excluded from abiraterone 
treatment based on the presence of comorbid car-
diovascular disorders.
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